In the in vivo studies, combination therapy using an inhibitor of miRNA-1246 and paclitaxel led to the significant inhibition of tumor growth, which was associated with reduced proliferation of cancer cells, downregulation of PDGFRβ, and upregulation of Cav1 in cancer tissue. The gene discussed is CAV1; the disease is cancer.